Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen.
Doser
N
N
Sudre
P
P
Telenti
A
A
Wietlisbach
V
V
Nicod
P
P
Darioli
R
R
Mooser
V
V
D000328:Adult; D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D010078:Oxazines / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D019438:Ritonavir / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014280:Triglycerides / Q000097:blood
D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D017320:HIV Protease Inhibitors; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D014280:Triglycerides; C098320:efavirenz; D019438:Ritonavir